Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease

Grundy, 2019, J Am Coll Cardiol, 73, e285, 10.1016/j.jacc.2018.11.003 Baigent, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Fruchart, 2008, The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient, Diab Vasc Dis Res, 5, 319, 10.3132/dvdr.2008.046 Xiao, 2016, Pharmacological targeting of the atherogenic dyslipidemia complex: the next frontier in CVD prevention beyond lowering LDL Ccholesterol, Diabetes, 65, 1767, 10.2337/db16-0046 Otvos, 2002, Measurement issues related to lipoprotein heterogeneity, Am J Cardiol, 90, 22i, 10.1016/S0002-9149(02)02632-2 Packard, 2003, Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein, Biochem Soc Trans, 31, 1066, 10.1042/bst0311066 Adiels, 2008, Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome, Arterioscler Thromb Vasc Biol, 28, 1225, 10.1161/ATVBAHA.107.160192 Berneis, 2002, Metabolic origins and clinical significance of LDL heterogeneity, J Lipid Res, 43, 1363, 10.1194/jlr.R200004-JLR200 Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA), Atherosclerosis, 192, 211, 10.1016/j.atherosclerosis.2006.05.007 Lawler, 2017, Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol, J Am Heart Assoc, 6 Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931, 10.1161/CIRCULATIONAHA.108.816181 Aday, 2018, Lipoprotein particle profiles, standard lipids, and peripheral artery disease incidence, Circulation, 138, 2330, 10.1161/CIRCULATIONAHA.118.035432 Varbo, 2013, Remnant cholesterol as a causal risk factor for ischemic heart disease [published correction in J Am Coll Cardiol 2019;73:987–8], J Am Coll Cardiol, 61, 427, 10.1016/j.jacc.2012.08.1026 Varbo, 2014, Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment, Pharmacol Ther, 141, 358, 10.1016/j.pharmthera.2013.11.008 Varbo, 2013, Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation, Circulation, 128, 1298, 10.1161/CIRCULATIONAHA.113.003008 Varbo, 2015, Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population, Clin Chem, 61, 533, 10.1373/clinchem.2014.234146 Varbo, 2014, Remnant cholesterol and ischemic heart disease, Curr Opin Lipidol, 25, 266, 10.1097/MOL.0000000000000093 Hoogeveen, 2014, Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study, Arterioscler Thromb Vasc Biol, 34, 1069, 10.1161/ATVBAHA.114.303284 Varbo, 2018, Remnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the copenhagen general population study, Clin Chem, 64, 219, 10.1373/clinchem.2017.279463 Varbo, 2019, Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population, Ann Neurol, 85, 550, 10.1002/ana.25432 Saeed, 2018, Remnant-like particle cholesterol, low-density lipoprotein triglycerides, and incident cardiovascular disease, J Am Coll Cardiol, 72, 156, 10.1016/j.jacc.2018.04.050 Vallejo-Vaz, 2018, Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT Trial, Circulation, 138, 770, 10.1161/CIRCULATIONAHA.117.032318 Ridker, 2005, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women, N Engl J Med, 352, 1293, 10.1056/NEJMoa050613 Lee, 2005, Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial, JAMA, 294, 56, 10.1001/jama.294.1.56 Ridker, 1999, Homocysteine and risk of cardiovascular disease among postmenopausal women, JAMA, 281, 1817, 10.1001/jama.281.19.1817 Duran, 2019, Plasma placental growth factor concentrations are elevated well in advance of type 2 diabetes mellitus onset: prospective data from the WHS, J Am Heart Assoc, 8 Ito, 2011, Development of a homogeneous assay for measurement of small dense LDL cholesterol, Clin Chem, 57, 57, 10.1373/clinchem.2010.149559 Pradhan, 2008, Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk, Circulation, 117, 823, 10.1161/CIRCULATIONAHA.107.719369 Therneau, 1999, Computing the Cox model for case cohort designs, Lifetime Data Anal, 5, 99, 10.1023/A:1009691327335 Barlow, 1994, Robust variance estimation for the case-cohort design, Biometrics, 50, 1064, 10.2307/2533444 Langholz, 2007, Computational methods for case-cohort studies, Computational Statistics & Data Analysis, 51, 3737, 10.1016/j.csda.2006.12.028 Wolkewitz, 2016, A full competing risk analysis of hospital-acquired infections can easily be performed by a case-cohort approach, J Clin Epidemiol, 74, 187, 10.1016/j.jclinepi.2015.11.011 Durrleman, 1989, Flexible regression models with cubic splines, Stat Med, 8, 551, 10.1002/sim.4780080504 Adiels, 2006, Overproduction of large VLDL particles is driven by increased liver fat content in man, Diabetologia, 49, 755, 10.1007/s00125-005-0125-z Mamo, 1998, Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma, Atherosclerosis, 141, S63, 10.1016/S0021-9150(98)00220-2 Zilversmit, 1973, A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins, Circ Res, 33, 633, 10.1161/01.RES.33.6.633 Mahley, 1985, Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia, Ann N Y Acad Sci, 454, 209, 10.1111/j.1749-6632.1985.tb11860.x Nordestgaard, 1995, Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media, Arterioscler Thromb Vasc Biol, 15, 534, 10.1161/01.ATV.15.4.534 Nordestgaard, 1996, The vascular endothelial barrier--selective retention of lipoproteins, Curr Opin Lipidol, 7, 269, 10.1097/00041433-199610000-00002 Rutledge, 2000, Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL, Circ Res, 86, 768, 10.1161/01.RES.86.7.768 Shaikh, 1991, Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans, Arterioscler Thromb, 11, 569, 10.1161/01.ATV.11.3.569 Takahashi, 2004, The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor, J Atheroscler Thromb, 11, 200, 10.5551/jat.11.200 Moore, 2013, Macrophages in atherosclerosis: a dynamic balance, Nat Rev Immunol, 13, 709, 10.1038/nri3520 Chen, 2016, Atherosclerotic plaque rupture: identifying the straw that breaks the camel's back, Arterioscler Thromb Vasc Biol, 36, e63, 10.1161/ATVBAHA.116.307993 Bentzon, 2014, Mechanisms of plaque formation and rupture, Circ Res, 114, 1852, 10.1161/CIRCRESAHA.114.302721 Matsuo, 2012, Plaque characteristics and arterial remodeling in coronary and peripheral arterial systems, Atherosclerosis, 223, 365, 10.1016/j.atherosclerosis.2012.05.023 Polonsky, 2014, High-risk plaque in the superficial femoral artery of people with peripheral artery disease: prevalence and associated clinical characteristics, Atherosclerosis, 237, 169, 10.1016/j.atherosclerosis.2014.08.034 Carmena, 2004, Atherogenic lipoprotein particles in atherosclerosis, Circulation, 109, III2 Austin, 1988, Low-density lipoprotein subclass patterns and risk of myocardial infarction, JAMA, 260, 1917, 10.1001/jama.1988.03410130125037 Ehara, 2002, Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases, J Diabetes Complications, 16, 60, 10.1016/S1056-8727(01)00210-0 Nishi, 2002, Oxidized LDL in carotid plaques and plasma associates with plaque instability, Arterioscler Thromb Vasc Biol, 22, 1649, 10.1161/01.ATV.0000033829.14012.18 Sigala, 2010, Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability, J Vasc Surg, 52, 704, 10.1016/j.jvs.2010.03.047 Otvos, 1999, Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy, Clin Cardiol, 22, II21 Everett, 2006, The relative strength of C-reactive protein and lipid levels as determinants of ischemic stroke compared with coronary heart disease in women, J Am Coll Cardiol, 48, 2235, 10.1016/j.jacc.2006.09.030 Willey, 2013, Cholesterol level and stroke: a complex relationship, JAMA Intern Med, 173, 1765, 10.1001/jamainternmed.2013.10100 Imamura, 2009, LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study, Stroke, 40, 382, 10.1161/STROKEAHA.108.529537 Valdes-Marquez, 2019, Relative effects of LDL-C on ischemic stroke and coronary disease: a Mendelian randomization study, Neurology, 92, e1176 Ference, 2019, Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease, JAMA, 321, 364, 10.1001/jama.2018.20045 Hansen, 2019, Low-grade inflammation in the association between mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis: a study of more than 115000 individuals from the general population, Clin Chem, 65, 321, 10.1373/clinchem.2018.294926 Nordestgaard, 2016, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology, Circ Res, 118, 547, 10.1161/CIRCRESAHA.115.306249 Bhatt, 2019, Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia, N Engl J Med, 380, 11, 10.1056/NEJMoa1812792 Rajamani, 2009, Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial, Lancet, 373, 1780, 10.1016/S0140-6736(09)60698-X Fruchart, 2017, Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia, Cardiovasc Diabetol, 16, 124, 10.1186/s12933-017-0602-y Arai, 2017, Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia, Atherosclerosis, 261, 144, 10.1016/j.atherosclerosis.2017.03.032 Pradhan, 2018, Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study, Am Heart J, 206, 80, 10.1016/j.ahj.2018.09.011